Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4 (IgG4) antibody, imsidolimab ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization of imsidolimab, which has successfully completed two ...

Under the terms of the agreement, Vanda will make to Anaptys an upfront payment of $10M and a $5M payment for existing drug supply. Anaptys is also eligible to receive up to $35M for future ...

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers ...